VAKSIN ROTAVIRUS: APAKAH SUDAH WAKTUNYA DIMASUKKAN DALAM PROGRAM IMUNISASI NASIONAL DI INDONESIA?

Abstract

Background: Two rotavirus vaccines have been available
for use. The objectives of the study to examine disease burden
of diare rotavirus and the cost and effectiveness of a rotavirus
vaccination program in Indonesia.
Material and Methods:  Data on direct and indirect costs of
children with rotavirus diarrhea were established in Purworejo
District and Yogyakarta city. It was extrapolated to national
estimates on the basis of the projected birth cohort in 2007
and diarrhea morbiditity rate at national level. The main outcome
measures were economic burden and cost-effectiveness ratio
(Rupiah per DALY averted).
Results: The disease burden is equivalent to an economic
burden of an estimated Rp390.4 billion in medical direct costs,
Rp 67.3 bilion in nonmedical direct costs, and 70.4 billion rupiah
in indirect costs. From the health care system and community
perspectives, universal vaccination of infants at a cost of less
than US $12,7 for a vaccine dose would be a cost-effective of
public health intervention.
Conclusions and Recommendation: In Indonesia, rotavirus
vaccination would reduce the morbidity burden of rotavirus
infection, but would not be cost-effective unless the price of
vaccine decreased considerably. At the current price of
vaccine, universal vaccination program for rotavirus would
not be recommended.
Keywords: burden of disease, rotavirus diarrhea vaccine,
cost-effectiveness